Clinical trial
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With…
NCT00311766 · RegeneRx Biopharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00311766 |
|---|---|
| Title | A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa |
| Lead sponsor | RegeneRx Biopharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epidermolysis Bullosa |
| Intervention type | Drug |
| Interventions | Thymosin Beta 4, Placebo |
| Enrollment | 30 |
| Start date | Feb 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Nov 1, 2012 |
| First posted | Apr 6, 2006 |
| Last update posted | May 12, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: